STOCK TITAN
  1. Home
  2. News
  3. VYNT

Vyant Bio, Inc. - VYNT STOCK NEWS

Welcome to our dedicated page for Vyant Bio news (Ticker: VYNT), a resource for investors and traders seeking the latest updates and insights on Vyant Bio stock.

Vyant Bio, Inc. (Nasdaq: VYNT) is a pioneering biotechnology company focused on transforming lives through the integration of human biology, engineering, and data science. Under the leadership of Andrew LaFrence, who serves as President, Chief Executive Officer, and Chief Financial Officer, Vyant Bio aims to revolutionize the biomedical field with innovative solutions.

Vyant Bio's core business involves leveraging cutting-edge technologies and a multidisciplinary approach to develop solutions that address critical medical needs. The company is dedicated to harnessing the power of data science and engineering to create more effective and personalized treatments.

Recent achievements include the development of state-of-the-art therapeutic platforms that utilize human biology to enhance drug discovery processes. These platforms are designed to improve the accuracy and efficiency of identifying viable drug candidates, thereby accelerating the pathway from research to clinical application.

Vyant Bio is currently involved in several key projects, including collaborations with leading pharmaceutical companies and academic institutions. These partnerships are aimed at expanding the scope and impact of their research and development efforts.

Financially, Vyant Bio is committed to maintaining a strong balance sheet and ensuring sustainable growth. The company continuously explores new opportunities for funding and strategic alliances to support its ambitious research initiatives.

For those seeking the latest updates and relevant information about Vyant Bio, the company's official website, www.vyantbio.com, offers comprehensive resources. Forward-looking statements and additional investor information can also be found on the website.

News

Vyant Bio Provides Update on Winddown Activities

Rhea-AI Summary
Vyant Bio, Inc. (OTC: VYNT) provides an update to shareholders regarding its winddown activities following the sale of its assets. The Board of Directors has filed its Certificate of Dissolution with the State of Delaware, and the stock will cease trading on the OTC after December 29, 2023. Shareholders may receive distributions, if any, in the fourth quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
none
-
News

Vyant Bio Provides Update on Winddown Activities

Rhea-AI Summary
Vyant Bio, Inc. (OTC: VYNT) provides an update on its winddown activities and liquidation plan. The company anticipates filing a Certificate of Dissolution in late December 2023, after which the common stock will cease to trade. Shareholders may receive liquidation payments ranging from $0.16 to $0.29 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.76%
Tags
none
-
News

Vyant Bio Announces Stockholder Approval of Plan of Dissolution

Rhea-AI Summary
Vyant Bio, Inc. announces the results of its special meeting of stockholders, where they voted in favor of the proposal to approve the voluntary liquidation and dissolution of the company. The proposal received the affirmative vote of holders of 94.0% of the shares casting votes and 53.1% of the company's total outstanding common shares. Vyant Bio's board will determine a date for filing a Certificate of Liquidation and Dissolution with the State of Delaware.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.27%
Tags
none
News

Vyant Bio Announces Completion of StemoniX Asset Sale

Rhea-AI Summary
Vyant Bio, Inc. has completed the sale of its assets, according to a recent announcement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.17%
Tags
none
-
News

Vyant Bio Announces Stockholder Approval of Proposed Asset Sale; 64,110 Votes Needed to Approve Plan of Dissolution; and Adjournment of Special Meeting of Stockholders

Rhea-AI Summary
Vyant Bio announces approval of sale of assets at special meeting of stockholders
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.58%
Tags
none
-
News

Vyant Bio Announces 77,522 Votes Needed to Approve Sale of Assets 175,721 Votes Needed to Approve Winddown of Business Adjournment of Special Meeting of Stockholders

Rhea-AI Summary
Vyant Bio adjourns special meeting to provide additional time for stockholders to vote on proposals
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.25%
Tags
none
News

Vyant Bio Announces Adjournment of Special Meeting of Stockholders

Rhea-AI Summary
Vyant Bio's special meeting of stockholders was adjourned without conducting any business to provide more time for voting on proposals. The adjourned meeting will reconvene on October 11, 2023. The company continues to solicit votes for Proposal 1 and Proposal 2, which require 50% or more of outstanding shares to vote in favor for them to pass. At the time of adjournment, both proposals had received affirmative votes from over 95% of shares casting votes. Stockholders who have already voted do not need to vote again.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.44%
Tags
none
-
News

Vyant Bio Announces Adjournment of Special Meeting of Stockholders

Rhea-AI Summary
Vyant Bio's special meeting of stockholders adjourned without conducting any business to provide more time for voting on proposals to approve the sale of assets and voluntary liquidation. There is significant support for the proposals, with approximately 90% of shares casting affirmative votes. Stockholders who have already voted do not need to vote again.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
none
-
News

AxoSim Enters Into a Definitive Agreement to Acquire Vyant Bio's StemoniX Assets

Rhea-AI Summary
AxoSim to Acquire microBrain™ Assets from Vyant Bio's StemoniX Subsidiary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15%
Tags
acquisition
News

Vyant Bio Announces Last Day of Trading on Nasdaq and Filing of Form 15 for Voluntary Nasdaq Delisting and SEC Deregistration

Rhea-AI Summary
Vyant Bio, a biotechnology company, has announced its plans to voluntarily delist its securities from Nasdaq and suspend its reporting obligations under the Exchange Act. The company expects its securities to be deregistered 90 days after the filing of the Form 25 with the SEC. The common stock will be quoted on the OTC Pink Open Market starting on or about May 15, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.51%
Tags
none

FAQ

What is the market cap of Vyant Bio (VYNT)?

The market cap of Vyant Bio (VYNT) is approximately 1.2M.

What does Vyant Bio, Inc. specialize in?

Vyant Bio, Inc. specializes in integrating human biology, engineering, and data science to develop innovative medical solutions.

Who is the CEO of Vyant Bio, Inc.?

Andrew LaFrence is the President, Chief Executive Officer, and Chief Financial Officer of Vyant Bio, Inc.

What are the recent achievements of Vyant Bio, Inc.?

Vyant Bio has developed advanced therapeutic platforms that enhance drug discovery processes, leveraging human biology for more accurate and efficient results.

What are some of Vyant Bio's key projects?

Vyant Bio is involved in collaborations with leading pharmaceutical companies and academic institutions to expand the scope and impact of their R&D efforts.

How can I get the latest updates about Vyant Bio, Inc.?

For the latest updates and information, visit Vyant Bio's official website at www.vyantbio.com.

What is Vyant Bio's approach to financial sustainability?

Vyant Bio is committed to maintaining a strong balance sheet and sustainable growth through strategic funding and alliances.

Does Vyant Bio, Inc. engage in partnerships?

Yes, Vyant Bio collaborates with leading pharmaceutical companies and academic institutions to enhance their research and development initiatives.

Where can I find investor information about Vyant Bio, Inc.?

Investor information is available on Vyant Bio's official website at www.vyantbio.com.

What is the significance of Vyant Bio's therapeutic platforms?

Vyant Bio's therapeutic platforms utilize human biology to improve drug discovery, making the process more accurate and efficient.

How does Vyant Bio integrate data science into its operations?

Vyant Bio leverages data science to develop personalized treatments and innovative medical solutions.

Stock VYNT logo
Vyant Bio, Inc.

OTC:VYNT

VYNT Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

VYNT Stock Data

1.23M
5.10M
18.78%
0.64%
3.27%
Biotechnology
Healthcare
Link
United States
Cherry Hill